Search research articles
Contact Us
Filters
Showing results (81-90 of 118) with videos related to
Page
of 12
Sort By:
JTO Clinical and Research Reports
|
May 2, 2022
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
Marie-Hélène Denault, Shelley Kuang, Aria Shokoohi, et al.
NPJ Precision Oncology
|
October 25, 2022
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
Dean A Regier, Samantha Pollard, Melanie McPhail, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 20, 2007
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
Angela M Davies, Cheryl Ho, Alex S Metzger, et al.
Clinical Lung Cancer
|
December 25, 2013
Third-line chemotherapy in small-cell lung cancer: an international analysis
Demetrios Simos, Golmehr Sajjady, Melissa Sergi, et al.
Quantitative Imaging in Medicine and Surgery
|
December 18, 2023
Tensor radiomics: paradigm for systematic incorporation of multi-flavoured radiomics features
Arman Rahmim, Amirhosein Toosi, Mohammad R Salmanpour, et al.
Current Oncology (Toronto, Ont.)
|
August 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Lancet Regional Health. Americas
|
November 28, 2024
Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study
Emanuel Krebs, Deirdre Weymann, Cheryl Ho, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 31, 2026
Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center Cohort
Heather Halperin, Amanda J W Gibson, Ali Hussein, et al.
Investigational New Drugs
|
September 10, 2013
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
Cheryl Ho, Angela M Davies, Randeep S Sangha, et al.
Translational Lung Cancer Research
|
September 21, 2020
EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
Alexandra Pender, Curtis Hughesman, Elaine Law, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 118) with videos related to
Sort By:
Page
of 12
JTO Clinical and Research Reports
|
May 2, 2022
Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
Marie-Hélène Denault, Shelley Kuang, Aria Shokoohi, et al.
NPJ Precision Oncology
|
October 25, 2022
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
Dean A Regier, Samantha Pollard, Melanie McPhail, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 20, 2007
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
Angela M Davies, Cheryl Ho, Alex S Metzger, et al.
Clinical Lung Cancer
|
December 25, 2013
Third-line chemotherapy in small-cell lung cancer: an international analysis
Demetrios Simos, Golmehr Sajjady, Melissa Sergi, et al.
Quantitative Imaging in Medicine and Surgery
|
December 18, 2023
Tensor radiomics: paradigm for systematic incorporation of multi-flavoured radiomics features
Arman Rahmim, Amirhosein Toosi, Mohammad R Salmanpour, et al.
Current Oncology (Toronto, Ont.)
|
August 25, 2023
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, et al.
Lancet Regional Health. Americas
|
November 28, 2024
Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study
Emanuel Krebs, Deirdre Weymann, Cheryl Ho, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 31, 2026
Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center Cohort
Heather Halperin, Amanda J W Gibson, Ali Hussein, et al.
Investigational New Drugs
|
September 10, 2013
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
Cheryl Ho, Angela M Davies, Randeep S Sangha, et al.
Translational Lung Cancer Research
|
September 21, 2020
EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
Alexandra Pender, Curtis Hughesman, Elaine Law, et al.
Page
of 12